Business
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
Dr. Sam S. Chang, Professor of Urology at Vanderbilt Cancer Program, to host the program “A Deep Dive with Patrick Soon-Shiong: Next-Generation Immunotherapy
About this update from Immunitybio, Inc.
[{"type":"text","content":"\n\nDr. Sam S. Chang, Professor of Urology at Vanderbilt Cancer Program, to host the program “A Deep Dive with Patrick Soon-Shiong: Next-Generation Immunotherapy for NMBIC”\n\n\n\n\nDiscussion about the basis for ANKTIVA’s Breakthrough Therapy designation and the novel mechanism of how the IL-15 superagonist achieves durable complete responses in BCG unresponsive NMIBC\n\n\n\n CULVER CITY, Calif.--(BUSINESS WIRE)--\nThe Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio, Inc. (NASDAQ: IBRX), a next-generation immunotherapy company, will discuss the implications of the recent FDA approval of ANKTIVA® (nogapendekin alfa inbakicept-pmln) for use in combination with bacillus Calmette-Guerin (BCG) for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors at the American Urological Association Annual Meeting (AUA 2024) this week in San Antonio, Texas.\n\n\nPatrick Soon-Shiong, M.D., will discuss the company’s novel FDA-designated Breakthrough Therapy ANKTIVA, and its potential as an alternative therapy to radical surgery for patients with advanced cases of bladder cancer that have failed to respond to the current standard of care of BCG adminstered alone. Dr. Soon-Shiong will describe how the tumor evades BCG therapy and how ANKTIVA rescues BCG when combined with ANKTIVA, revealing details of ImmunityBio’s Cancer Moonshot strategy of transforming “MHC Negative” (cold) bladder cancer cells as a mechanism of tumor evasion from BCG, to “MHC Positive” (hot) tumors via ANKTIVA’s activation of NK and T cells, resulting in complete durable response.\n\n\n“The realization that this transformation of MHC- to MHC+ could rescue exhausted or immune-evaded T cells was the basis of our Cancer Moonshot announced in 2016. Our QUILT program provided insight that this strategy of transforming MHC- to MHC+ applies to all tumor types that have entered the escape phase, and the approval of ANKTIVA marks our first step to the next evolution of immunotherapy by orchestrating both the innate and adaptive immune system. I very much look forward to elaborating on the details with Dr. Sam Chang at the AUA conference,” said Dr. Patrick Soon-Shiong.\n\n\nHosting Dr. Soon-Shiong will be Dr. Sam S. Chang, M.D., Professor of Urology and Chief Surgical Officer of the Vanderbilt Ingram C...